When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Last reviewed: 20 Mar 2025
Last updated: 05 Nov 2024

Summary

Definition

History and exam

Key diagnostic factors

  • history of diabetes mellitus
  • presence of risk factors
  • foot ulcer
  • foot pain
  • loss of protective sensation
  • foot deformity
  • fever or chills

Other diagnostic factors

  • malaise
  • anorexia
  • foot erythema
  • oedema of foot, ankle, or calf
  • absent pedal pulses
  • fluctuance

Risk factors

  • previous history of foot ulcer
  • previous history of amputation
  • sensory neuropathy
  • peripheral arterial disease
  • end-stage renal disease
  • foot deformities
  • limited foot and/or ankle joint mobility
  • visual impairment
  • poor glycaemic control
  • Charcot’s neuro-osteoarthropathy
  • obesity
  • obstructive sleep apnoea

Diagnostic investigations

Investigations to consider

  • FBC
  • blood glucose level
  • microbiological culture
  • erythrocyte sedimentation rate
  • C-reactive protein
  • renal function
  • ankle/toe pressures
  • x-ray foot
  • angiography
  • MR angiography
  • CT angiography
  • intra-arterial digital subtraction angiography
  • MRI foot
  • arterial duplex ultrasound

Emerging tests

  • serum procalcitonin
  • 18F-fluorodeoxyglucose (FDG)-PET/CT
  • 99mTc-exametazime Hexa Methyl Propylene Amine Oxime (HMPAO)-labeled white blood cell scintigraphy
  • 99mTc-labeled Ubiquicidin (UBI) SPECT/CT single photon emission computed tomography (SPECT/CT)

Treatment algorithm

Contributors

Authors

Frances L. Game, MBBCh, FRCP

Consultant Diabetologist and Clinical Director of R&D

Department of Diabetes and Endocrinology

University Hospitals of Derby and Burton NHS Foundation Trust

Derby

UK

Disclosures

FLG is in receipt of research grants from the NIHR and MRC. She is National Clinical Lead for the National Diabetes Foot Care Audit of England and Wales, and is an NHS England regional Clinical Director. She Chairs the International Working Group of the Diabetic Foot (IWGDF), and chaired both the Classification and Wound Healing Working Groups which produced the 2023 IWGDF guidelines. FLG is an author of a reference cited in the topic.

Acknowledgements

Dr Frances L. Game would like to gratefully acknowledge Dr Neal R. Barshes, Dr Joseph L. Mills, and Dr David G. Armstrong, previous contributors to this topic.

Disclosures

NRB and DGA declare that they have no competing interests. JLM is a consultant for, and owns stocks in, Nangio TX; a member of the scientific advisory committees for Cesca, AnGes, and AstraZeneca; and the Co-National Principal Investigator for the Voyager trial of rivaroxaban in peripheral arterial disease patients undergoing intervention (funding for this institutional research grant goes directly to the Baylor College of Medicine).

Peer reviewers

Simon Ashwell, MBChB, MD, FRCP

Consultant Physician of Diabetes and Endocrinology

Diabetes Care Centre

The James Cook University Hospital

Middlesbrough

UK

Disclosures

SA declares that he has no competing interests.

Use of this content is subject to our disclaimer